Congestive Heart Failure (CHF) Treatment Devices Market By Product (Cardiac Pacemaker, Implantable Cardioverter Defibrillators, Cardiac Resynchronization therapy devices, Counter Pulsation Devices, Ventricular Assist Devices (VADs)), By End-User (Hospitals and clinic, Specialized Cardiovascular Disease Treatment Centers, Ambulatory surgery centres) By Geography, Size, Share, Global Industry Analysis Report, Forecast, 2021-2030

Published On: Apr-2022 Base Year: 2021 No Of Pages: 135 Historical Data: 2017 - 2020 Formats: PDF Report ID: 54233187

Industry Statistics and Insights

The global congestive heart failure (CHF) treatment devices market will witness a robust CAGR of 8.31%, valued at $17.53 billion in 2021, expected to appreciate and reach $35.96 billion by 2030, confirms Strategic Market Research. North America leads the market share, followed by the European Union.

Cardiovascular Diseases are Majorly Classified into Six Types

Coronary Artery Disease (Due to Narrowing of Arteries)
Heart Valve Disease (Due to Malfunctioning of Valve)
Arrhythmia (Due to Abnormal Heart rhythm)
Congestive Heart Failure (CHF) or Heart Failure (Due to Loss of Pumping Strength)
Heart Muscle Disease (Due to Thickening of Heart Valve)
Congenital Heart (Acquired by birth)

According to the study published in the European Society of Cardiology journal, the number of people with heart failure has roughly doubled in the previous three decades. The above estimate suggests that 70 million people in 2022 will suffer from heart failure worldwide. Congestive Heart failure is a chronic (long-term) progressive condition when the heart cannot efficiently pump enough oxygen-rich blood to the remaining part of the body. Over time, the heart muscle loses its capacity to contract or has a mechanical defect preventing blood circulation. As a result, it can't cope with the body's demands, and blood is retrieved to the heart faster as compared to its pumping out, causing it to get congested or backed up.

The weakening of the heart's pumping ability causes congestion of blood in the lungs, feet, and legs, called edema, leading to tiredness and shortness of breath.

The Most Common Reasons of Congestive Heart Failure are

Coronary artery disease.
Diabetes
High blood pressure
Previous heart attack
Cardiomyopathy

Left-sided CHF is the most common kind of CHF. It occurs when the left ventricle doesn't properly pump blood out to the body. There are two kinds of left-sided CHF: Systolic heart failure (Ineffective contraction of the heart) and Diastolic failure (ineffective relaxation of the heart). Systolic dysfunction is treatable with various medications. However, we have yet to establish the benefits of medicines for people with diastolic heart failure. Various tests are used to diagnose heart conditions like Blood-Test ( Lipid Profile), Chest X-Ray, ECG, Echocardiogram, Stress Tests, Cardiac catheterization and MRI.

Drivers - Lifestyle changes, High-stress levels, Dietary habits, and Comorbidity

Key factors that vitalize the growth of the Congestive Heart Failure (CHF) Treatment Devices Market Trend:-

Lifestyle Changes- Poor diet, lack of exercise, unhealthy weight gain, increased smoking, and excessive alcohol intake increase the risk of cardiac Failure.

High-Stress levels- Worry, stress, anger, and sadness among employees worldwide have risen over the past decade. According to Gallup Global Emotions Survey 2019, around one-third of people worldwide reported feeling stressed, worried, and angry.

Comorbidities- In addition, chronic heart failure is driven by disorders like coronary artery disease, sleep apnea, heart defects, irregular heartbeats, diabetes mellitus, obesity, and kidney difficulties, which synergistically influence the prevalence of chronic heart failure. As per AME Medical Journal, The most frequent causes of HF with known etiology is ischemic heart disease (42.3% of all cases), followed by chronic obstructive pulmonary disease (37.0%), mitral valve disease (4.3%), aortic valve disease (3.4%), rheumatic heart disease (3.0%), myocarditis (2.6%) and endocarditis (1.4%).

Rising Old Age Population- Since CHF is more common in the elderly population; they are the major acquirers and users of CHF Treatment devices. According to World Bank data and World Population Prospects, the share of the old age population in CHF Treatment devices (65 years and more) will rise from 9.32% in 2020 to 16% by 2050.

Congestive Heart Failure Treatment Devices Market Based on End User

Restraints - Cost, Reimbursement Procedures

However, stringent regulatory requirements, the high cost of these devices, and unfavorable reimbursement policies will likely hamper the industry's growth. According to cost-of-illness studies on heart failure published in PubMed, The total annual costs per patient ranged from $868 for South Korea to $25,532 for Germany. The global economic burden of CHF is estimated at $108 billion per annum, with $65 billons attributed to direct and $43 billion to indirect costs.

Opportunities

High Incidence-Increasing demand and decreasing willingness for organ donation, the need for safe and effective therapy, and the increasing prevalence of chronic heart failure is anticipated to drive the worldwide demand for these devices. As per the research published by CDC (Centers for Disease Control and Prevention), more than 6 Mn adults in the USA have heart failure, and over 23 million worldwide.

Health expenditure- Supporting government laws and initiatives in emerging economies and improving healthcare infrastructure to raise public knowledge of CVDs are growth boosters for the total industry. According to a Journal published in the National Library of Medicine (NLM), Heart Failure was responsible for an estimated health expenditure of around USD 31 Bn, which is equivalent to more than 10 % of the total health expenditure for cardiovascular diseases in the United States (US).

Technological Advancements- With recent dramatic leaps in sensor and soft robotics technology, scientists are turning to innovative medical devices for heart failure to prolong the life of patients.

Demographic and Regional Opportunities- Congestive heart failure is a prevalent ailment among the elderly. Congestive heart failure strikes netizens over the age of 75 ten times more frequently than it does to the younger ones. The research of the Department of Economic and Social Affairs estimates around 703 million people aged 65 or over in 2019 worldwide. Eastern and South-Eastern Asia region was home to the largest number of the older population (261 million), followed by Europe and Northern America (over 200 million).

Market Analysis Of Different Segments Covered in the Report

Based on Product

Cardiac Pacemaker
Implantable Cardioverter Defibrillators (ICDs)
Cardiac Resynchronization therapy devices (CRT)
Counter Pulsation Devices
Ventricular Assist Devices (VADs)

Based on End-User

Hospitals and clinic
Specialized Cardiovascular Disease Treatment Centers
Ambulatory surgery centers

Regional Coverage Analysis

Based on Region

North America
Europe
Asia-Pacific
Middle-East and Africa
Latin America

Congestive Heart Failure Treatment Devices Market Based on Product

Segments Analysis & Insights

By Product Type, Implantable Cardioverter Defibrillators (ICDs) are the largest in congestive heart failure treatment devices due to technological innovations. As a result, the ventricular assist devices (VADs) market is predicted to develop significantly throughout the forecast period.

By End-users, the Hospitals segment is expected to grab the congestive heart failure devices market share. The rise of government funds for the development of hospitals across the globe is expected to drive the market growth of this segment. According to a study published in NCBI, Total medical costs in the US are projected to increase from $31.1 billion (in 2020) to $53.1 billion (by 2030). Most (80%) of the costs attributed to HF are related to hospitalization, assuming the continuation of current hospitalization practices.

By Region, North America is predicted to be the largest market for congestive heart failure devices, followed by Europe due to the high frequency of cardiovascular disorders. According to AHA's Heart Disease and Stroke Statistics 2017, the number of people diagnosed with heart failure in the US is increasing and projected to rise by 46 percent by 2030, resulting in more than 8 Mn people with heart failure.

The region has witnessed more stress due to financial issues, workplace atmosphere, and other family problems. According to World Economic Forum Report, workers in the US and Canada recorded the highest daily stress levels globally at 57%. The percolating effects of the ongoing stress and trauma are precarious for the country's youth, Generation Z (Gen Z). According to the APA's 2020 Stress in America study, Gen Z is more stressed than Millenials, Gen X, Baby Boomers, or older adults. Because of the growing geriatric population in India and China, the Asia-Pacific region is expected to be the fastest Growing Market in congestive heart failure treatment devices.

Congestive Heart Failure Treatment Devices Market Report Coverage

Report Attribute	Details
Forecast Period	2021 - 2030
The market size value in 2021	USD 17.53 billion
The revenue forecast in 2030	USD 35.96 billion
Growth rate	CAGR of 8.31%
The base year for estimation	2021
Historical data	2017 – 2020
Unit	USD Billion, CAGR (2021 - 2030)
Segmentation	By Product, By End User, By Region
By Product	Cardiac Pacemaker, Cardiac Resynchronization Therapy (CRT), Implantable Cardioverter Defibrillators (ICDs), Counter Pulsation Devices, Ventricular Assist Devices (VADs)
By End-User	Hospitals and clinics, Specialized Cardiovascular Disease Treatment Centers, Ambulatory surgery centres
By Region	Asia Pacific, North America, Europe, and LAMEA
Country Scope	US, Mexico, Canada, Germany, UK, France, China, Japan, India etc.
Company Usability Profiles	Berlin Heart GmbH, Abiomed, Inc., Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International, Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic plc, ReliantHeart Inc., and St. Jude Medical, Inc.
Pricing and purchase options	Customized buying options are available to meet your exact research needs.

Global Congestive Heart Failure Treatment Devices Market Competitive Landscape Analysis

This global CHF treatment devices industry report has the competitive landscape analysis, which details the most significant competitors operating in a global market. The comparison is based on overall revenue generation, market initiatives, company overview, R&D investment, production analysis, value chain optimization, market share financials, company strengths and weaknesses, global presence, heart failure device companies, production capacity, production sites and facilities, market potential, and other variables.

• Medtronic

• Abiomed

• Berlin Heart GmbH

• Biotronik SE & Co. KG

• Boston Scientific Corporation

• Jarvik Heart

• LivaNova PLC

• HeartWare International

• ReliantHeart

• CVRx

• St. Jude Medical

Congestive Heart Failure Treatment Devices Market Based on Region

Recent Developments

In March 2022, FineHeart's ICOMS FLOWMAKER Algorithms were granted a patent in the United States. The ICOMS FLOWMAKER, the world's first and only fully implantable electrophysiological cardiac support device for treating severe heart failure, is covered by the patent "Method for managing a heart pump." The business expects to treat 200,000 patients with severe heart failure every year.

In February 2022, US FDA approved Jardiance (empagliflozin) to treat adults with heart failure. Jardiance became the first and only heart failure medication to show a statistically significant reduction in heart failure-related deaths and hospitalizations, independent of ejection fraction. Also, it reduces the risk of cardiovascular death in adults with type 2 diabetes having cardiovascular disease and lower blood sugar.

In March 2021, BERLIN HEALS received Breakthrough Device Designation (BDD) from FDA for its Device for Cardiac Microcurrent Therapy ("C-MIC"). The C-MIC is an implanted device that uses two electrodes to supply a steady, low-current electrical DC to the heart. The FDA's Breakthrough Devices program helps companies create medical devices that have the potential to treat or diagnose life-threatening or profoundly debilitating diseases.

In January 2020, FAST BioMedical Announced the Successful Completion of the Multi-center Acute Congestive Heart Failure Trial in Germany. The measures developed by FAST BioMedical has the potential to be a game-changer in managing volume and volume-related kidney damage in patients with acute congestive heart failure.

Various Devices that Key Market Leaders Develop

Product	Function	Key players
PLATINIUM	ICDs and CRT-Ds	Liva Nova
Freezor	For treatment of a common heart rhythm condition	Medtronic
BAROSTIM NEO	Neuromodulation Device (regulate heart, kidney and vascular function)	CVRx
Rivacor	Heart monitoring at home	Biotronic

Frequently Asked Question About This Report

b: Recently the FDA approved Entresto, a combination of sacubitril and valsartan, for the treatment of heart failure patients with preserved ejection fraction (HFpEF)

b: Loop diuretics should be used first, with thiazides added if the fluid overload is refractory. After that, patients should take diuretic treatment with a ß-blocker, a low-salt diet, and an ACE inhibitor.

b: Modify daily activities, avoid stress, take enough rest, take a heart-healthy diet, and maintain low sodium and fat intake. However, special care has to be taken for patients with low haemoglobin, thyroid disease, diabetes and kidney disease.

b: Modern treatment for heart disease includes Cardiac catheterization, Cardiac resynchronization therapy, and Coronary artery bypass surgery. Some congestive heart failure devices used are Echocardiogram, Electrocardiogram (EKG or ECG), Implantable cardioverter-defibrillator and others. Also, NCBI has recommended some mobile apps for heart failure patients.

b: CHF is not curable, but early detection and treatment are possible. Following a proper treatment plan that includes lifestyle changes may help improve their quality of life.

b: The four pillars are diuretics, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and Lanoxin.

b: The global congestive heart failure treatment devices market size was $17.53 Bn in 2021 and is predicted to reach $35.96 Bn by 2030, with a CAGR of 8.31%.

b: The global congestive heart failure treatment devices market is expected to grow at a compound annual growth rate (CAGR) of 8.31% from 2021 to 2030 to reach USD35.96 billion by 2030.

Sources

https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Report.pdf

https://www.gallup.com/analytics/349280/gallup-global-emotions-report.aspx

https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930493/

https://www.cdc.gov/heartdisease/heart_failure.htm